Olema Pharmaceuticals, Inc.
6 clinical trials · Sponsor
◉ Watch Olema Pharmaceuticals, Inc.
| Record | Firm | Date |
|---|---|---|
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (NCT07085767) | Olema Pharmaceuticals, Inc. | 2025-11-03 |
| Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors (NCT06784193) | Olema Pharmaceuticals, Inc. | 2024-12-16 |
| Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer (NCT05508906) | Olema Pharmaceuticals, Inc. | 2022-08-31 |
| A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients (NCT05266105) | Olema Pharmaceuticals, Inc. | 2021-12-10 |
| A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer (NCT04505826) | Olema Pharmaceuticals, Inc. | 2020-08-13 |
Track Olema Pharmaceuticals, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.